[Apropos of accommodation-convergence synkinesia in unilateral aphakia corrected by a contact lens].

P. Francois,M. Woillez,M. Ducret

1965-02-01

Abstract:

What problem does this paper attempt to address?

Idiosyncratic drug-induced liver injury: an overview

S Hyder Hussaini,Elizabeth A Farrington

DOI: https://doi.org/10.1517/14740338.6.6.673

Abstract:Drug-induced liver injury (DILI) encompasses a spectrum of clinical disease ranging from mild biochemical abnormalities to acute liver failure. The majority of adverse liver reactions are idiosyncratic, occurring in most instances 5-90 days after the causative medication was last taken. The diagnosis of DILI is clinical, based on history, probability of the suspect medication as a cause of liver injury and exclusion of other hepatic disease. DILI can be hepatocellular (predominant rise in alanine transaminase), cholestatic (predominant rise in alkaline phosphatase) or mixed liver injury. An elevated bilirubin level more than twice the upper limit of normal in patients with hepatocellular liver injury implies severe DILI, with a mortality of approximately 10% and with an incidence rate of 0.7-1.3 per 100,000. Although acute liver failure is rare, 13-17% of all acute liver failure cases are attributed to idiosyncratic drug reactions. Response to drug withdrawal may be delayed up to 1 year with cholestatic liver injury with occasional subsequent progressive cholestasis known as the vanishing bile duct syndrome. Overall, chronic disease may occur in up to 6% even if the offending drug is withdrawn. Antibiotics and NSAIDs are the most common cause of DILI. Statins rarely cause significant liver injury whereas antiretroviral therapy is associated with hepatotoxicity in 10% of treated patients. Multiple mechanisms of DILI have been implicated, including TNF-alpha-activated apoptosis, inhibition of mitochondrial function and neoantigen formation. Risk factors for DILI include age, sex and genetic polymorphisms of drug-metabolising enzymes such as cytochrome P450. In patients with human immunodeficiency virus, the presence of chronic viral hepatitis increases the risk of antiretroviral therapy hepatotoxicity. Over the next decade, the combination of accurate case ascertainment of DILI via clinical networks and the application of genomics and proteomics will hopefully lead to accurate prediction of risk of DILI, so that pharmacotherapy can be optimised with avoidance of adverse hepatic events.
Exploring cognitive reserve in multiple sclerosis: New findings from a cross-sectional study

D. Nunnari,M. D. De Cola,Antonio Costa,C. Rifici,P. Bramanti,S. Marino

DOI: https://doi.org/10.1080/13803395.2016.1200538

2016-07-13

Journal of Clinical and Experimental Neuropsychology

Abstract:ABSTRACT Introduction: The cognitive reserve (CR) hypothesis attempts to explain the discrepancy between brain damage and clinical manifestations in neurodegenerative diseases. Recently the concept of CR was applied to the multiple sclerosis (MS) model. Our aim is to investigate the impact of demographic and clinical variables on cognitive outcome in MS patients. Method: A total of 72 MS patients were assessed by Rao’s Brief Repeatable Battery of Neuropsychological Tests (BRB-N), Cognitive Reserve Index Questionnaire (CRIq), and high field magnetic resonance examination. We performed a multivariate linear regression analysis, including each cognitive test scores as dependent variables and CRI together with age, normalized brain volume (NBV), normalized cortical volume (NCV), expanded disability severity scale (EDSS) score, and disease duration as independent variables. Moreover, we assessed whether one of the CRI subscores (CRI–Education, CRI–WorkingActivity, CRI–LeisureTime) predicted cognitive performance more than the other. Finally, to assess the CR hypothesis in our sample, we conducted the same analyses including the interaction term CRI × NCV. Results: From the multiple regression analysis, it emerged that the CRI total score influenced sustained attention, concentration, information processing speed, and verbal learning. Among the three CRI subscores, CRI–Education and CRI–WorkingActivity had the most influence. Age and EDSS score were the other significant predictors. We did not find evidence for a moderation effect of CR on negative influence of atrophy on cognitive status. Conclusions: This study focused on the contribution of CR to predict neuropsychological outcome in MS. We used a new standardized questionnaire to provide a global index including three main source of CR: education, working activity, and leisure time activities. Our preliminary findings suggest that the CR is an important predictor of better performance on cognitive tests in MS patients. However, at this stage of the study, we are unable to confirm the CR hypothesis.
Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Feng-Qin Hou,Zheng Zeng,Gui-Qiang Wang

DOI: https://doi.org/10.1007/s12013-012-9373-y

2012-01-01

Cell Biochemistry and Biophysics

Abstract:We investigated clinical features, therapy, and outcomes of patients hospitalized for drug-induced liver injury (DILI). DILI resolution was defined as liver biochemistry values back to normal or lower than CIOMS laboratory criteria; Chronicity was defined as persistent biochemical abnormality for >6 months after drugs’ withdrawal. Three-hundred cases were reviewed retrospectively; mean age 51 (13–86) years, and 204 (68 %) were females. It included 267 (89 %) hepatocellular injury, 16 (5.3 %) cholestatic injury, and 17 (5.7 %) mixed injury cases. In hepatocellular injury group, 197 (73.8 %) patients with TBIL < 10× ULN included 142 (72.1 %) females and 70 (26.2 %) patients with TBIL ≥ 10× ULN included 39 (55.7 %) females ( P = 0.012). Of 70 patients (TBIL ≥ 10× ULN), 20 were treated with steroid step-down therapy (79 ± 26 days) and others with non-steroid therapy. The steroid therapy group showed higher DILI resolution rate ( P = 0.029) and shorter recovery time ( P = 0.012). Notably, 274/300 (91.3 %) patients resolved, 18/300 (6 %) developed chronic liver injury, 7/300 (2.3 %) died, and one patient received liver transplantation. In death group, TBIL, ALB, PT, and PTA revealed more severe abnormality than in recovery group. In 121/300 (40.3 %) patients, use of herbal medicines was the leading cause of liver injury, followed by antibiotics, cardiovascular drugs, and endocrine drugs. We concluded that step-down steroid therapy for DILI improved curative effect, shortened disease course, and was safe.
Idiosyncratic drug-induced liver injury: an update on the 2007 overview

S Hyder Hussaini,Elizabeth Anne Farrington

DOI: https://doi.org/10.1517/14740338.2013.828032

Abstract:Introduction: Idiosyncratic drug induced liver injury (DILI) is rare, with an incidence of approximately 19 per 100,000 treated individuals. Areas covered: An update on the epidemiology, pathogenic mechanisms, diagnosis, outcome, risk factors for idiosyncratic drug-induced hepatotoxicity, specific classes of drug hepatotoxicity and biomarkers to predict DILI are covered. Cumulative drug exposure and HLA phenotypes play an important role in the pathogenesis of DILI. Patients who present with suspected DILI and jaundice should have biliary obstruction and acute viral hepatitis, including hepatitis E excluded. Immune-mediated DILI will respond to steroid therapy. Patients with an elevated bilirubin and a hepatocellular pattern of liver function tests have severe liver injury with a mortality of greater than 10% and a risk of acute liver failure. Women have an increased risk of hepatocellular DILI. Antibiotics, anticonvulsants, and antidepressant therapy remain the commonest causes of DILI in the Western Hemisphere. Statin therapy rarely causes severe liver injury. Expert opinion: The establishment of prospective registries for DILI has provided valuable data on the pathogenesis and outcome of DILI. Drug-specific computerised causality assessment tools should improve the diagnosis of DILI. The clinical utility of genetic polymorphisms associated with drug-specific DILI is limited.
Clinical management of patients with drug-induced liver injury (DILI)

Einar S Björnsson

DOI: https://doi.org/10.1002/ueg2.12113

Abstract:Drug-induced liver injury (DILI) should be considered in all patients with recent elevation of liver tests without obvious etiology and normal hepatobiliary imaging. There is currently no biomarker that is helpful in diagnosis which relies on clinical and laboratory findings. Diagnosis is dependent on temporal relationship with a recently started drug or herbal and dietary supplement and elevated liver tests with exclusion of competing etiologies. The implicated agent should be discontinued and the patient should be observed closely. This is particularly important in patients with jaundice who have approximately 10% risk of liver related mortality and/or need for liver transplantation. There is no specific therapy for DILI which is only symptomatic such as for itching. Patients with jaundice and coagulopathy usually require hospitalization.
[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Xiao-Li Wang,Zhao-Hui Yu,Shao-Hua Chen,You-Ming Li

DOI: https://doi.org/10.3321/j.issn:0578-1426.2008.05.011

2008-01-01

Abstract:OBJECTIVE:To analyse the etiology, clinical features and prognosis of drug-induced liver disease (DILD), in order to draw more attention to this problem.METHODS:332 cases of DILD admitted to the First Affiliated Hospital of Zhejiang University from 2000-2006 were retrospectively analysed.RESULTS:A variety of drugs, including herbal medicines (27.1% of our total cases), anti-tuberculosis drugs (13.3%) and immunosuppressive drugs (10.8%) caused drug-induced liver damage. The hepatocellular type (43.1%) was the most common type seen clinically and the mixed type (32.5%) and cholestatic type (24.4%) were somewhat less.CONCLUSIONS:A variety of medicines may cause DILD; herbal medicines, anti-tuberculosis drugs and immunosuppressive drugs were frequently found to be responsible, the hepatocellular type was the most common, while the mixed type and cholestatic type were somewhat less. Serum albumin, total bile acids, direct bilirubin and blood prothrombin time are important predictors of the prognosis of DILD.
Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Shuang Zhao,Haoshuang Fu,Tianhui Zhou,Minghao Cai,Yan Huang,Qinyi Gan,Chenxi Zhang,Cong Qian,Jiexiao Wang,Zhenglan Zhang,Xiaolin Wang,Xiaogang Xiang,Qing Xie

DOI: https://doi.org/10.3389/fimmu.2022.772368

IF: 7.3

2022-04-12

Frontiers in Immunology

Abstract:Background & Aims Drug-induced liver injury (DILI) is one of the leading causes of liver failure with some of the patients progressed to chronic DILI. The mechanisms underlying the severity and chronicity of DILI are poorly elucidated and the biomarkers are limited. Metabolites and gut microbiota played a crucial role in the development of various liver diseases. Herein, a systematic analysis of serum metabolites and gut microbiota was performed in DILI patients, aiming to identify metabolites correlated with the progression and clinical prognosis of DILI. Methods Various serum metabolites were quantitated using a metabolite array technology in this prospective study. Gut microbiome compositions and the expression profiles of liver genes were determined in patients with DILI and healthy controls. Results Metabolomic analysis revealed that bile acids (BAs) and polyunsaturated fatty acids (PUFAs) were closely related to DILI severity and chronicity respectively. The ratios of serum primary/secondary BAs and omega-6/omega-3 PUFAs were elevated in DILI patients. A model established by adrenic acid (AdA) and aspartic acid (Asp) exerts good performance for predicting the chronicity of DLIL. Hepatic transcriptome revealed enhanced expression of PUFA peroxidation and supressed expression of BA synthesis related genes in DILI patients. In addition, Lactic acid bacteria and BA converting bacteria were increased in gut of DILI patients. Besides, elevated serum malondialdehyde (MDA) and fibroblast growth factor 19 (FGF19) was observed in DILI patients. Conclusion BAs and PUFAs could be potent markers for the severity and chronicity of DILI respectively. The panel of AdA and Asp could be ideal predictive model for the risk of chronicity at the acute stage of DILI. Gut microbiota might act as a negative feedback mechanism to maintain the homeostasis of BAs and PUFAs via FGF19 signalling and PUFA saturation, respectively. Our study revealed novel biomarkers for severe and chronic DILI and provided new therapeutic targets for DILI.

immunology
Effects of sodium dodecylsulphate, dye concentration and paraprotein on coomassie blue dye-binding assays for protein in urine.

C. W. Lim,W. Chisnall,Y. Stokes,R. Pratt,M. Crooke

DOI: https://doi.org/10.1016/S0009-9120(88)80081-X

IF: 3.625

1988-10-01

Clinical Biochemistry

Abstract:
Drug-induced liver injury: a comprehensive review

Tom Hosack,Djamil Damry,Sujata Biswas

DOI: https://doi.org/10.1177/17562848231163410

2023-01-01

Therapeutic Advances in Gastroenterology

Abstract:Drug-induced liver injury (DILI) remains a challenge in clinical practice and is still a diagnosis of exclusion. Although it has a low incidence amongst the general population, DILI accounts for most cases of acute liver failure with a fatality rate of up to 50%. While multiple mechanisms of DILI have been postulated, there is no clear causal relationship between drugs, risk factors and mechanisms of DILI. Current best practice relies on a combination of high clinical suspicion, thorough clinical history of risk factors and timeline, and extensive hepatological investigations as supported by the international Roussel Uclaf Causality Assessment Method criteria, the latter considered a key diagnostic algorithm for DILI. This review focuses on DILI classification, risk factors, clinical evaluation, future biomarkers and management, with the aim of facilitating physicians to correctly identify DILI early in presentation.

gastroenterology & hepatology
Dissecting the molecular pathophysiology of drug-induced liver injury

Hui Ye,Leonard J Nelson,Manuel Gómez Del Moral,Eduardo Martínez-Naves,Francisco Javier Cubero

DOI: https://doi.org/10.3748/wjg.v24.i13.1373

2018-04-07

Abstract:Drug-induced liver injury (DILI) has become a major topic in the field of Hepatology and Gastroenterology. DILI can be clinically divided into three phenotypes: hepatocytic, cholestatic and mixed. Although the clinical manifestations of DILI are variable and the pathogenesis complicated, recent insights using improved preclinical models, have allowed a better understanding of the mechanisms that trigger liver damage. In this review, we will discuss the pathophysiological mechanisms underlying DILI. The toxicity of the drug eventually induces hepatocellular damage through multiple molecular pathways, including direct hepatic toxicity and innate and adaptive immune responses. Drugs or their metabolites, such as the common analgesic, acetaminophen, can cause direct hepatic toxicity through accumulation of reactive oxygen species and mitochondrial dysfunction. The innate and adaptive immune responses play also a very important role in the occurrence of idiosyncratic DILI. Furthermore, we examine common forms of hepatocyte death and their association with the activation of specific signaling pathways.
Features and Outcomes from a Retrospective Study of 570 Hospitalized Chinese Patients with Drug-Induced Liver Injury.

Lili Pang,Wanna Yang,Fengqin Hou

DOI: https://doi.org/10.1016/j.clinre.2017.08.003

IF: 3.189

2018-01-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:Aims: To investigate the clinical features and outcomes of hospitalized patients with drug induced liver injury (DILI). Methods: The medical records of hospitalized patients with DILI from January 1997 through July 2016 were reviewed. Results: Five hundred seventy cases were reviewed, of which 381 (66.8%) were female. Four hundred fifty-eight cases (80.4%) presented with hepatocellular injury, 53 (9.3%) with cholestatic injury and 59 (10.4%) with mixed injury. Chronicity was more common in cholestatic and mixed injury cases than in hepatocellular cases (P<0.001). In the hepatocellular injury group, patients in the severity score >= 3 group were younger than the patients in the severity score <= 2 group (P=0.040). In the entire cohort, 487/570 (85.4%) patients resolved, 57/570 (10.0%) developed chronic liver injury, and 11/570 (1.9%) died. Thirty-two acute DILI patients with severity scores of 3 received steroid therapy, but no improvement was observed in the recovery time or resolution rate of these patients compared with that of the non-steroid group. Chinese herbal medicines were the most commonly used drugs, followed by antimicrobials, cardiovascular agents, endocrine agents, and nonsteroidal anti-inflammatory drugs (NSAIDs). Conclusions: Hepatocellular injury was the most common DILI pattern, and 10.0% of patients developed chronic DILI. Steroid therapy was not associated with an improved recovery time or survival in acute severe DILI patients. (C) 2017 Published by Elsevier Masson SAS.
Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis

Shuai-shuai Chen,Ying Huang,Yu-ming Guo,Shan-shan Li,Zhuo Shi,Ming Niu,Zheng-sheng Zou,Xiao-he Xiao,Jia-bo Wang

DOI: https://doi.org/10.3389/fmed.2021.640799

IF: 3.9

2021-03-29

Frontiers in Medicine

Abstract:Background: Chronic drug-induced liver injury (DILI) occurs in up to 20% of all DILI patients. It presents a chronic pattern with persistent or relapsed episodes and may even progress to cirrhosis. However, its underlying development mechanism is poorly understood. Aims: To find serum metabolite signatures of chronic DILI with or without cirrhosis, and to elucidate the underlying mechanism. Methods: Untargeted metabolomics coupled with pattern recognition approaches were used to profile and extract metabolite signatures from 83 chronic DILI patients, including 58 non-cirrhosis (NC) cases, 14 compensated cirrhosis (CC) cases, and 11 decompensated cirrhosis (DC) cases. Results: Of the 269 annotated metabolites associated with chronic DILI, metabolic fingerprints associated with cirrhosis (including 30 metabolites) and decompensation (including 25 metabolites), were identified. There was a significantly positive correlation between cirrhosis-associated fingerprint (eigenmetabolite) and the aspartate aminotransferase-to-platelet ratio index (APRI) ( r = 0.315, P = 0.003). The efficacy of cirrhosis-associated eigenmetabolite coupled with APRI to identify cirrhosis from non-cirrhosis patients was significantly better than APRI alone [area under the curve (AUC) value 0.914 vs. 0.573]. The decompensation-associated fingerprint (eigenmetabolite) can effectively identify the compensation and decompensation periods (AUC value 0.954). The results of the metabolic fingerprint pathway analysis suggest that the blocked tricarboxylic acid cycle (TCA cycle) and intermediary metabolism, excessive accumulation of bile acids, and perturbed amino acid metabolism are potential mechanisms in the occurrence and development of chronic DILI-associated cirrhosis. Conclusions: The metabolomic fingerprints characterize different stages of chronic DILI progression and deepen the understanding of the metabolic reprogramming mechanism of chronic DILI progression to cirrhosis.

medicine, general & internal
OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK

Fernando Bessone,Nelia Hernández,Maria I Schinoni,Manuel Mendizabal,Pedro Montes,Adriana Sanchez,Daniela Chiodi,Ezequiel Ridruejo,Vinicius Nunes,Genario Santos,Ximena Pazos,Hugo Tanno,Federico Tanno,Martin Tagle,Marco Arrese,Alina Zerega,Carla Bianchi,Laura Reyes,Marcos Girala,Raymundo Parana,M Virginia Reggiardo,Daiana Arnedillo,Antonella Cordone,Gisela Gualano,Fernanda Jaureguizahar,Camilla Stephens,Inmaculada Medina-Cáliz,Mercedes Robles-Díaz,Aida Ortega-Alonso,Elvira Bonilla,Miren García-Cortés,Ismael Alvarez-Alvarez,Hao Niu,M Isabel Lucena,Raúl J Andrade

DOI: https://doi.org/10.1016/j.aohep.2023.101274

IF: 3.388

2024-02-01

Annals of Hepatology

Abstract:Introduction and Objectives The Latin American DILI (LATINDILI) Network is an international registry of prospectively identified drug-induced liver injury (DILI) cases to enhance case characterization. We aimed to analyze features and outcomes of DILI in Latin America. Materials and Methods Information of DILI cases included in the LATINDILI database between 2011 and July 2022 was collected and analyzed. Results Of 468 patients included, 13 had positive rechallenge and 5 recurrent DILI (different drugs). Mean age was 49 years (range 14- 89), 62% women. The most common type of injury was hepatocellular (62%). Overall, 42% of patients were hospitalized. Most cases were mild/moderate, but 6.2% were considered severe, and 4.1% resulted in death/liver transplantation. Overall, eleven cases (2.4%) developed chronic DILI (no biochemical resolution within one year), and nine had drug-induced autoimmune-like hepatitis (1.9%). Histological information was available for 80 patients (17%), of whom 5 had chronic cholestasis with ductopenia. The most frequent drugs were amoxicillin-clavulanate (12%), herbal and dietary supplements (HDS, 9%), anabolic androgenic steroids (4.9%), anti- tuberculosis medications (anti-TB) and nitrofurantoin (4.3% each). Among the 15 most common causative agents, all but azathioprine, were associated with cases fulfilling nR-based Hy's law. However, only anti-TB, nimesulide and HDS were associated with worst outcome cases, while many were not, such as amoxicillin-clavulanate, nitrofurantoin and diclofenac. Causative agents more common in women included methyldopa (100%) nitrofurantoin (95%) and nimesulide (86%), while cyproterone (100%) and phenytoin (67%) were more common in men. Conclusions The increasing number of liver injuries associated with HDS is a major concern in Latin America. The predictive value of the nR-based Hy's law is drug-specific. These findings have regulatory implications for the promotion of public health, as common DILI- causing drugs in Latin America are either second-line drugs, no longer in use, or have been withdrawn from other markets due to liver toxicity. Funding: AEMPS, CIBERehd,ISCIII-FEDER (PI21/01248,PI-0310-2018).

gastroenterology & hepatology
A comparative analysis of the clinical features of acute and chronic drug-induced liver injury

Tongtong JI,Haiying LU,Ning TAN,Yanyan YU,Xiaoyuan XU

DOI: https://doi.org/10.3969/j.issn.1001-5256.2020.07.021

2020-01-01

Abstract:ObjectiveTo investigate the similarities and differences in the clinical features of acute versus chronic drug-induced liver injury (DILI). MethodsClinical data were collected from 183 patients who were hospitalized and diagnosed with DILI in Department of Infectious Diseases, Peking University First Hospital, from January 2015 to December 2018, and the patients were divided into acute group with 138 patients and chronic group with 45 patients. Related data were collected, including general information, underlying diseases, history of suspected drugs, history of allergy, drinking history, symptoms and signs, laboratory examination, radiological examination, liver biopsy, treatment, and prognosis. Roussel Uclaf Causality Assessment Method (RUCAM) score was determined for all patients diagnosed with DILI, and the type and severity of liver injury were determined. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups; a logistic regression analysis was used to investigate the influencing factors for chronicity of DILI. ResultsAmong the 138 patients in the acute group, 105 (76.1%) had DILI caused by Chinese herbal medicine and 15 (10.9%) had DILI caused by antibiotics, while among the 45 patients in the chronic group, 33 (73.3%) had DILI caused by Chinese herbal medicine and 5 (11.1%) had DILI caused by antibiotics. There were significant differences between the two groups in sex (χ2=4.774, P=0.029), type of liver injury (χ2=9.848, P=0.02), and severity of DILI (χ2=8.012, P=0.046); 778% of the patients in the chronic group had a RUCAM score of ≤6, while 79.7% of the patients in the acute group had a RUCAM score of ≥6, and there was a significant difference between the two groups (χ2=21.471, P=0.002). There were significant differences between the two groups in platelet count (PLT), alanine aminotransferase (ALT), aspartate aminotransferase, direct bilirubin, creatinine, detection rate of ANA, and detection rate of SMA (all P＜0.05). Compared with the acute group, the chronic group had a significantly longer incubation period and a significantly higher proportion of patients with liver cirrhosis or no response to treatment (all P＜0.05); there was a significant difference between the two groups in the proportion of patients treated with glucocorticoids (χ2=27.109, P＜0.05) or glucocorticoids combined with azathioprine (χ2=27.408, P＜0.05). A total of 16 patients (11.6%) in the acute group and 7 (15.6%) in the chronic group had autoimmune hepatitis-like DILI; 29 patients in the acute group underwent liver pathological examination, among whom 2(6.9%) had an unknown cause, while 27 patients in the chronic group underwent liver pathological examination, among whom 6(22.2%) had an unknown cause. ALT (odds ratio ［OR］=0.997, 95% confidence interval ［CI］: 0.985-0.999, P=0.003) and PLT (OR=0997, 95%CI: 0.986-0.998, P=0.013) were independent predictive factors for chronicity of DILI. ConclusionCompared with acute DILI, chronic DILI is more common in female patients and is difficult to diagnose, with a long incubation period, a higher proportion of patients with cholestasis type, and a higher detection rate of autoantibody, and it requires glucocorticoid and immunosuppressive therapy more and tends to have poorer prognosis. ALT and PLT may be independent predictive factors for the chronicity of DILI.
Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Ashwin Rao,Jody A Rule,Bilal Hameed,Daniel Ganger,Robert J Fontana,William M Lee

DOI: https://doi.org/10.14309/ajg.0000000000001655

2022-04-01

Abstract:Introduction: Idiosyncratic drug-induced liver injury (DILI) is the second leading cause of acute liver failure (ALF) in the United States. Our study aims were to characterize secular trends in the implicated agents, clinical features, and outcomes of adults with DILI ALF over a 20-year period. Methods: Among 2,332 patients with ALF enrolled in the ALF Study Group registry, 277 (11.9%) were adjudicated as idiosyncratic DILI ALF (INR ≥ 1.5 and hepatic encephalopathy) through expert opinion. The 155 cases in era 1 (January 20, 1998-January 20, 2008) were compared with the 122 cases in era 2 (January 21, 2008-January 20, 2018). Results: Among 277 cases of DILI ALF, 97 different agents, alone or in combination, were implicated: antimicrobials, n = 118 (43%); herbal/dietary supplements (HDS), n = 42 (15%); central nervous system agents/illicit substances, n = 37 (13%); oncologic/biologic agents, n = 29 (10%); and other, n = 51 (18%). Significant trends over time included (i) an increase in HDS DILI ALF (9.7% vs 22%, P < 0.01) and decrease in antimicrobial-induced DILI ALF (45.8% vs. 38.5%, P = 0.03) and (ii) improved overall transplant-free survival (23.5%-38.7%, P < 0.01) while the number of patients transplanted declined (46.4% vs 33.6%, P < 0.03). Discussion: DILI ALF in North America is evolving, with HDS cases rising and other categories of suspect drugs declining. The reasons for a significant increase in transplant-free survival and reduced need for liver transplantation over time remain unclear but may be due to improvements in critical care, increased NAC utilization, and improved patient prognostication.
Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

Yihan Qian,Jie Zhao,Hailong Wu,Xiaoni Kong

DOI: https://doi.org/10.1007/s00204-024-03886-0

2024-10-13

Archives of Toxicology

Abstract:Drug-induced liver injury (DILI) is an acute liver injury that poses a significant threat to human health. In severe cases, it can progress into chronic DILI or even lead to liver failure. DILI is typically caused by either intrinsic hepatotoxicity or idiosyncratic metabolic or immune responses. In addition to the direct damage drugs inflict on hepatocytes, the immune responses and liver inflammation triggered by hepatocyte death can further exacerbate DILI. Initially, we briefly discussed the differences in immune cell activation based on the type of liver cell death (hepatocytes, cholangiocytes, and LSECs). We then focused on the role of various immune cells (including macrophages, monocytes, neutrophils, dendritic cells, liver sinusoidal endothelial cells, eosinophils, natural killer cells, and natural killer T cells) in both the liver injury and liver regeneration stages of DILI. This article primarily reviews the role of innate immune regulation mediated by these immune cells in resolving inflammation and promoting liver regeneration during DILI, as well as therapeutic approaches targeting these immune cells for the treatment of DILI. Finally, we discussed the activation and function of liver progenitor cells (LPCs) during APAP-induced massive hepatic necrosis and the involvement of chronic inflammation in DILI.

toxicology
Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

Inmaculada Medina-Cáliz,Judith Sanabria-Cabrera,Marina Villanueva-Paz,Lauryna Aukštikalnė,Camilla Stephens,Mercedes Robles-Díaz,José M Pinazo-Bandera,Miren García-Cortes,Isabel Conde,German Soriano,Fernando Bessone,Nelia Hernandez,Vinicius Nunes,Raymundo Paraná,M Isabel Lucena,Raúl J Andrade,Hao Niu,Ismael Alvarez-Alvarez

DOI: https://doi.org/10.1007/s00204-023-03630-0

Abstract:Idiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n = 881). DILI-DRESS cases were younger (47 vs. 53 years, respectively; p = 0.042) and presented more frequently with cholestatic/mixed damage (p = 0.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04-1.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11-69.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.
The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update

Einar Stefan Björnsson

DOI: https://doi.org/10.3390/ph17040520

IF: 4.6

2024-04-19

Pharmaceuticals

Abstract:The incidence and prevalence of drug-induced liver injury appear to be increasing globally, for example, with the introduction of checkpoint inhibitors. Several reviews have been published in the last decade on the epidemiology of DILI, both among hospitalized patients and in the general population, as well as from retrospective and prospective studies on DILI. Most of these reviews have not focused on newly recognized agents that have recently changed the landscape of DILI. Apart from liver injury associated with antibiotics, oncological agents, particularly checkpoint inhibitors, are increasingly being recognized as causing liver injury. The type of liver injury associated with these agents is not idiosyncratic but rather an indirect type of injury. Furthermore, recently, COVID-19 vaccines and green tea extract have been found to lead to liver injury. Checkpoint inhibitors have revolutionized the treatment of many malignancies, such as malignant melanoma, lung cancer, and renal cancer. Via the activation of T cells, they can increase immune activity against malignant cells, but at the same time, they can decrease immune tolerance and therefore lead to immune-related adverse effects in many organs. The most common adverse effect in clinical practice is liver injury. A recent prospective study demonstrated an 8% frequency of DILI due to the use of checkpoint inhibitors among patients with malignant melanoma and renal cancer. This rate is much higher than observed with drugs, leading to idiosyncratic liver injury. Shortly after the implementation of the worldwide vaccination program against COVID-19, several case reports were published on suspected vaccination-induced autoimmune-like hepatitis occurring shortly after the vaccination. At first, these reports were met with skepticism, but currently, around 100 reports have been published, and cases of positive recurrence have been reported. The clinical, biochemical, immunological, and histological features are indistinguishable from classic autoimmune hepatitis (AIH). These reactions are very similar to drug-induced autoimmune-like hepatitis (DI-ALH) due to drugs such as nitrofurantoin, minocycline, and infliximab, which do not relapse after a short course of corticosteroids, which is the general rule in classic autoimmune hepatitis (AIH). Green tea extract has been found to be a well-documented cause of acute hepatocellular liver injury with jaundice. A strong HLA association has been reported, showing a high prevalence of HLA-B*35:01 among patients suffering from green tea-induced liver injury. Overall, 3% of patients recruited in the DILIN study were supplemented with green tea extract as one of the ingredients. In a prospective population-based study from Iceland, green tea was implicated in approximately 8% of patients with DILI.

pharmacology & pharmacy,chemistry, medicinal
Arteriography in occult splenic rupture.

J. Horns,R. Barnes

Abstract:
S4576 Unique Case of Vanishing Bile Duct Syndrome Exacerbated by Noncompliance

Michael Farber,Garvita Sharma,Nicholas Condiles

DOI: https://doi.org/10.14309/01.ajg.0001047672.59319.cd

2024-10-26

The American Journal of Gastroenterology

Abstract:Drug induced liver injury (DILI) is the most common cause of liver injury. It can be dose-dependent, commonly associated with acetaminophen 1 or idiosyncratic, associated with amoxicillin-clavulanic acid 2 . In a small subset of patients, DILI may lead to vanishing bile duct syndrome (VBDS) HYPERLINK " https://pubmed.ncbi.nlm.nih.gov/25754159/ " 2, a prolonged cholestatic injury marked by loss of intrahepatic bile ducts.

gastroenterology & hepatology

[Apropos of accommodation-convergence synkinesia in unilateral aphakia corrected by a contact lens].

Idiosyncratic drug-induced liver injury: an overview

Exploring cognitive reserve in multiple sclerosis: New findings from a cross-sectional study

Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

Clinical management of patients with drug-induced liver injury (DILI)

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Effects of sodium dodecylsulphate, dye concentration and paraprotein on coomassie blue dye-binding assays for protein in urine.

Drug-induced liver injury: a comprehensive review

Dissecting the molecular pathophysiology of drug-induced liver injury

Features and Outcomes from a Retrospective Study of 570 Hospitalized Chinese Patients with Drug-Induced Liver Injury.

Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis

OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK

A comparative analysis of the clinical features of acute and chronic drug-induced liver injury

Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update

Arteriography in occult splenic rupture.

S4576 Unique Case of Vanishing Bile Duct Syndrome Exacerbated by Noncompliance